Brief: Elevar Therapeutics Resubmits NDA To U.S. FDA For Camrelizumab Plus Rivoceranib Astreatment For Unresectable Hepatocellular Carcinoma
23/09/2024 14:21
Sept 23 (Reuters) - HLB Inc 028300.KQ :
* ELEVAR THERAPEUTICS: RESUBMITS NDA TO U.S. FDA FOR
CAMRELIZUMAB
PLUS RIVOCERANIB ASTREATMENT FOR UNRESECTABLE HEPATOCELLULAR
CARCINOMA
Source text for Eikon: ID:nGNX5phNrP
Further company coverage: 028300.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLB
See all newsBrief: Hlb Co Resubmits New Drug Application Of Rivoceranib To Us FDA
Elevar-Hengrui hit with third FDA rejection for liver cancer therapy over manufacturing concerns (updated)
Brief: Elevar Therapeutics' NDA Resubmission For Rivoceranib With Camrelizumab Accepted By FDA
Brief: Elevar Therapeutics Resubmits NDA To U.S. FDA For Camrelizumab Plus Rivoceranib Astreatment For Unresectable Hepatocellular Carcinoma
Brief: Hlb Inc To Acquire 16 Billion Won Worth Of Shares In Neurotobe Pharmaceuticals Inc